| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2015 | 762 | 1.280 |
Why?
|
| Survivors | 7 | 2015 | 173 | 0.760 |
Why?
|
| Health Status Disparities | 3 | 2015 | 128 | 0.530 |
Why?
|
| Rural Population | 3 | 2013 | 216 | 0.510 |
Why?
|
| Brain Neoplasms | 8 | 2015 | 637 | 0.500 |
Why?
|
| Middle Aged | 45 | 2016 | 11851 | 0.450 |
Why?
|
| Neoplasms | 5 | 2013 | 754 | 0.450 |
Why?
|
| Aged | 39 | 2016 | 10263 | 0.430 |
Why?
|
| Female | 52 | 2016 | 19945 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2013 | 443 | 0.380 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 104 | 0.360 |
Why?
|
| Humans | 58 | 2017 | 32282 | 0.330 |
Why?
|
| Aged, 80 and over | 18 | 2016 | 3900 | 0.320 |
Why?
|
| Adult | 30 | 2016 | 9259 | 0.310 |
Why?
|
| Stroke | 6 | 2009 | 691 | 0.270 |
Why?
|
| Quality of Life | 9 | 2015 | 964 | 0.270 |
Why?
|
| Depression | 4 | 2015 | 420 | 0.270 |
Why?
|
| Male | 37 | 2016 | 19441 | 0.270 |
Why?
|
| Cognition Disorders | 3 | 2015 | 349 | 0.260 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 21 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 1224 | 0.240 |
Why?
|
| Lung Neoplasms | 2 | 2006 | 423 | 0.230 |
Why?
|
| Fatigue | 3 | 2015 | 76 | 0.230 |
Why?
|
| Indans | 2 | 2015 | 31 | 0.220 |
Why?
|
| Brain Ischemia | 5 | 2009 | 159 | 0.220 |
Why?
|
| Piperidines | 2 | 2015 | 137 | 0.210 |
Why?
|
| Plant Extracts | 2 | 2017 | 61 | 0.210 |
Why?
|
| Adaptation, Psychological | 2 | 2015 | 131 | 0.200 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 180 | 0.200 |
Why?
|
| Coronary Disease | 3 | 2011 | 226 | 0.190 |
Why?
|
| Emergency Service, Hospital | 3 | 2011 | 444 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2014 | 1437 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 595 | 0.180 |
Why?
|
| Glioblastoma | 2 | 2015 | 159 | 0.170 |
Why?
|
| Obesity | 4 | 2013 | 1111 | 0.170 |
Why?
|
| Glioma | 2 | 2014 | 137 | 0.170 |
Why?
|
| Risk Factors | 11 | 2013 | 3934 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 187 | 0.170 |
Why?
|
| Body Composition | 2 | 2016 | 327 | 0.160 |
Why?
|
| Thalidomide | 3 | 2011 | 32 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2013 | 167 | 0.160 |
Why?
|
| Inpatients | 2 | 2011 | 83 | 0.160 |
Why?
|
| Health Promotion | 2 | 2012 | 242 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2011 | 1050 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2015 | 3416 | 0.140 |
Why?
|
| Chest Pain | 2 | 2011 | 205 | 0.140 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2015 | 37 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 267 | 0.140 |
Why?
|
| Double-Blind Method | 6 | 2017 | 565 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2015 | 92 | 0.130 |
Why?
|
| Health Literacy | 2 | 2015 | 28 | 0.130 |
Why?
|
| Patient Preference | 2 | 2015 | 48 | 0.130 |
Why?
|
| European Continental Ancestry Group | 4 | 2015 | 1076 | 0.130 |
Why?
|
| Follow-Up Studies | 8 | 2015 | 2240 | 0.130 |
Why?
|
| Micronutrients | 1 | 2017 | 20 | 0.130 |
Why?
|
| Health Education | 2 | 2015 | 149 | 0.130 |
Why?
|
| African Americans | 2 | 2015 | 1335 | 0.120 |
Why?
|
| Phytotherapy | 2 | 2017 | 36 | 0.120 |
Why?
|
| United States | 7 | 2013 | 4072 | 0.120 |
Why?
|
| Electrocardiography | 3 | 2011 | 623 | 0.120 |
Why?
|
| Urban Population | 2 | 2013 | 91 | 0.120 |
Why?
|
| Connexin 43 | 1 | 2015 | 7 | 0.110 |
Why?
|
| Gap Junctions | 1 | 2015 | 8 | 0.110 |
Why?
|
| Head | 1 | 2016 | 56 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 23 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 137 | 0.110 |
Why?
|
| Corn Oil | 1 | 2014 | 4 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 1 | 2015 | 24 | 0.110 |
Why?
|
| Health Behavior | 2 | 2013 | 211 | 0.110 |
Why?
|
| User-Computer Interface | 1 | 2015 | 54 | 0.110 |
Why?
|
| Fish Oils | 1 | 2014 | 38 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2014 | 43 | 0.110 |
Why?
|
| Meningioma | 1 | 2015 | 59 | 0.110 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2015 | 90 | 0.110 |
Why?
|
| Continental Population Groups | 2 | 2013 | 228 | 0.110 |
Why?
|
| Taste Disorders | 1 | 2014 | 5 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 155 | 0.100 |
Why?
|
| Olfaction Disorders | 1 | 2014 | 7 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2013 | 242 | 0.100 |
Why?
|
| Saliva | 1 | 2014 | 39 | 0.100 |
Why?
|
| Ethnic Groups | 2 | 2013 | 450 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2015 | 193 | 0.100 |
Why?
|
| Internet | 2 | 2015 | 202 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2013 | 14 | 0.100 |
Why?
|
| Time Factors | 6 | 2015 | 2205 | 0.100 |
Why?
|
| Ubiquinone | 1 | 2013 | 7 | 0.100 |
Why?
|
| Exercise | 4 | 2013 | 603 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 219 | 0.100 |
Why?
|
| Social Welfare | 1 | 2012 | 4 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2013 | 100 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 27 | 0.090 |
Why?
|
| Vitamins | 1 | 2013 | 71 | 0.090 |
Why?
|
| Ginkgo biloba | 1 | 2012 | 20 | 0.090 |
Why?
|
| Ochratoxins | 1 | 2012 | 1 | 0.090 |
Why?
|
| Young Adult | 6 | 2016 | 2649 | 0.090 |
Why?
|
| Mood Disorders | 1 | 2012 | 20 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2015 | 757 | 0.090 |
Why?
|
| Hydroquinones | 1 | 2012 | 7 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2012 | 27 | 0.090 |
Why?
|
| Mutagens | 1 | 2012 | 6 | 0.090 |
Why?
|
| Family | 1 | 2012 | 112 | 0.090 |
Why?
|
| Feasibility Studies | 4 | 2015 | 308 | 0.090 |
Why?
|
| Panax | 1 | 2012 | 9 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2012 | 120 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 19 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2012 | 863 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 40 | 0.090 |
Why?
|
| Procarbazine | 1 | 2011 | 6 | 0.090 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2011 | 15 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 38 | 0.090 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 36 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2011 | 48 | 0.080 |
Why?
|
| Patient Admission | 1 | 2011 | 54 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 36 | 0.080 |
Why?
|
| Smoking | 2 | 2013 | 505 | 0.080 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2010 | 2 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 98 | 0.080 |
Why?
|
| Amenorrhea | 1 | 2010 | 4 | 0.080 |
Why?
|
| Menstruation | 1 | 2010 | 5 | 0.080 |
Why?
|
| Dystrophin | 1 | 2010 | 4 | 0.080 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2010 | 3 | 0.080 |
Why?
|
| Health Status | 1 | 2012 | 355 | 0.080 |
Why?
|
| Isometric Contraction | 1 | 2010 | 28 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2011 | 114 | 0.080 |
Why?
|
| Community Health Services | 1 | 2010 | 47 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 71 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 130 | 0.080 |
Why?
|
| Genome, Human | 2 | 2008 | 130 | 0.080 |
Why?
|
| Diet | 2 | 2012 | 383 | 0.080 |
Why?
|
| Nervous System Diseases | 2 | 2008 | 46 | 0.080 |
Why?
|
| Comorbidity | 1 | 2011 | 565 | 0.080 |
Why?
|
| Diet, Reducing | 1 | 2010 | 85 | 0.080 |
Why?
|
| Carboplatin | 2 | 2006 | 42 | 0.080 |
Why?
|
| Enteral Nutrition | 1 | 2010 | 29 | 0.080 |
Why?
|
| Crohn Disease | 1 | 2010 | 31 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2010 | 113 | 0.080 |
Why?
|
| Health Services | 1 | 2010 | 40 | 0.080 |
Why?
|
| Incidence | 5 | 2012 | 1241 | 0.080 |
Why?
|
| Dietary Supplements | 3 | 2017 | 188 | 0.070 |
Why?
|
| Triage | 1 | 2010 | 68 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2012 | 355 | 0.070 |
Why?
|
| Age Factors | 4 | 2013 | 1179 | 0.070 |
Why?
|
| Prognosis | 5 | 2013 | 1534 | 0.070 |
Why?
|
| Brain | 1 | 2016 | 965 | 0.070 |
Why?
|
| Mass Screening | 1 | 2011 | 256 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2011 | 3626 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2013 | 1479 | 0.070 |
Why?
|
| Echocardiography, Stress | 1 | 2008 | 23 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2008 | 36 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2010 | 250 | 0.070 |
Why?
|
| Personnel Selection | 1 | 2008 | 13 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2014 | 854 | 0.070 |
Why?
|
| Informed Consent | 1 | 2008 | 44 | 0.070 |
Why?
|
| Urodynamics | 1 | 2008 | 88 | 0.070 |
Why?
|
| Urination | 1 | 2008 | 69 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 36 | 0.060 |
Why?
|
| Lymphedema | 1 | 2007 | 5 | 0.060 |
Why?
|
| Motor Activity | 1 | 2009 | 332 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2009 | 1840 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2011 | 2316 | 0.060 |
Why?
|
| Topotecan | 1 | 2006 | 14 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 82 | 0.060 |
Why?
|
| Etoposide | 1 | 2006 | 38 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2008 | 243 | 0.060 |
Why?
|
| Medical Records | 1 | 2006 | 75 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 174 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 108 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2008 | 320 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2008 | 417 | 0.050 |
Why?
|
| Logistic Models | 3 | 2013 | 743 | 0.050 |
Why?
|
| Premenopause | 3 | 2010 | 53 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 883 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 821 | 0.050 |
Why?
|
| Survival Rate | 3 | 2012 | 893 | 0.050 |
Why?
|
| Memory | 2 | 2015 | 202 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 222 | 0.050 |
Why?
|
| Social Support | 2 | 2015 | 180 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 555 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1158 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 327 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2013 | 273 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2015 | 553 | 0.050 |
Why?
|
| Prevalence | 3 | 2010 | 955 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 729 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 853 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 603 | 0.040 |
Why?
|
| Affect | 2 | 2015 | 70 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 425 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2012 | 106 | 0.040 |
Why?
|
| Acute Disease | 2 | 2012 | 253 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 388 | 0.040 |
Why?
|
| Child | 3 | 2012 | 2435 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 381 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2013 | 200 | 0.040 |
Why?
|
| Primary Health Care | 2 | 2013 | 232 | 0.040 |
Why?
|
| Animals | 4 | 2015 | 8199 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 3519 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 471 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 717 | 0.040 |
Why?
|
| North Carolina | 2 | 2012 | 1300 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 324 | 0.030 |
Why?
|
| Forecasting | 2 | 2010 | 144 | 0.030 |
Why?
|
| Sex Factors | 2 | 2011 | 655 | 0.030 |
Why?
|
| Powders | 1 | 2017 | 8 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 773 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 32 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 32 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 2571 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2016 | 15 | 0.030 |
Why?
|
| Antioxidants | 1 | 2017 | 122 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2016 | 39 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 83 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 72 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2015 | 50 | 0.030 |
Why?
|
| Cell Communication | 1 | 2015 | 37 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 75 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2011 | 1425 | 0.030 |
Why?
|
| Myocardial Infarction | 2 | 2010 | 466 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2015 | 66 | 0.030 |
Why?
|
| Learning | 1 | 2015 | 84 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 192 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2015 | 80 | 0.030 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2014 | 4 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 31 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 100 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 45 | 0.030 |
Why?
|
| Life Change Events | 1 | 2013 | 20 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 757 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 499 | 0.020 |
Why?
|
| Ergocalciferols | 1 | 2013 | 3 | 0.020 |
Why?
|
| National Health Programs | 1 | 2013 | 6 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 262 | 0.020 |
Why?
|
| Spirituality | 1 | 2013 | 38 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2013 | 12 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2016 | 320 | 0.020 |
Why?
|
| Psychology | 1 | 2013 | 25 | 0.020 |
Why?
|
| Specialization | 1 | 2013 | 30 | 0.020 |
Why?
|
| Taxoids | 1 | 2013 | 50 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 167 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 56 | 0.020 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2012 | 13 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 168 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 50 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 184 | 0.020 |
Why?
|
| Lac Operon | 1 | 2012 | 5 | 0.020 |
Why?
|
| RNA, Transfer | 1 | 2012 | 3 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 484 | 0.020 |
Why?
|
| Genes, Suppressor | 1 | 2012 | 3 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2012 | 11 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 255 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2012 | 41 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 165 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 63 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 82 | 0.020 |
Why?
|
| Plasmids | 1 | 2012 | 50 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 456 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2013 | 130 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 245 | 0.020 |
Why?
|
| Patient Participation | 1 | 2013 | 90 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2012 | 135 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2012 | 88 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 18 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2011 | 14 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 24 | 0.020 |
Why?
|
| Cost Savings | 1 | 2011 | 34 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 547 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 40 | 0.020 |
Why?
|
| Drug Costs | 1 | 2011 | 46 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 151 | 0.020 |
Why?
|
| Adenosine | 1 | 2011 | 68 | 0.020 |
Why?
|
| Dobutamine | 1 | 2011 | 54 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 454 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 461 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 907 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 211 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 252 | 0.020 |
Why?
|
| Otitis Media | 1 | 2011 | 24 | 0.020 |
Why?
|
| Life Style | 1 | 2013 | 393 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 223 | 0.020 |
Why?
|
| Protestantism | 1 | 2010 | 6 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2010 | 19 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 60 | 0.020 |
Why?
|
| Counseling | 1 | 2010 | 93 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 477 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2010 | 40 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2010 | 52 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 126 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 96 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2011 | 85 | 0.020 |
Why?
|
| Medical Audit | 1 | 2010 | 15 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2011 | 204 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2010 | 18 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 68 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2010 | 135 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 235 | 0.020 |
Why?
|
| Safety Management | 1 | 2010 | 27 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 191 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2009 | 16 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 2009 | 25 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2009 | 124 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 324 | 0.020 |
Why?
|
| Seasons | 1 | 2009 | 73 | 0.020 |
Why?
|
| Exercise Test | 1 | 2010 | 217 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 171 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 161 | 0.020 |
Why?
|
| Angina, Unstable | 1 | 2008 | 13 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 242 | 0.020 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 167 | 0.020 |
Why?
|
| North America | 1 | 2008 | 31 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2008 | 28 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2007 | 26 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 1895 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 76 | 0.020 |
Why?
|
| Language | 1 | 2007 | 36 | 0.020 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2008 | 99 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 164 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2007 | 52 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2008 | 146 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2007 | 20 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 120 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 541 | 0.020 |
Why?
|
| Weight Gain | 1 | 2008 | 104 | 0.020 |
Why?
|
| Hospitalization | 1 | 2010 | 475 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 287 | 0.020 |
Why?
|
| Arm | 1 | 2007 | 42 | 0.020 |
Why?
|
| Siblings | 1 | 2006 | 23 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2006 | 50 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2008 | 454 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 144 | 0.020 |
Why?
|
| Hand | 1 | 2007 | 79 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2006 | 67 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 250 | 0.020 |
Why?
|
| Camptothecin | 1 | 2006 | 45 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 120 | 0.020 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 338 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2008 | 178 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 520 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 339 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 1233 | 0.010 |
Why?
|
| Genotype | 1 | 2007 | 702 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 390 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 979 | 0.010 |
Why?
|